Cover Image
市場調查報告書

病毒性結膜炎治療藥的全球市場:2016年∼2020年

Global Viral Conjunctivitis Drugs Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 354379
出版日期 內容資訊 英文 53 Pages
訂單完成後即時交付
價格
Back to Top
病毒性結膜炎治療藥的全球市場:2016年∼2020年 Global Viral Conjunctivitis Drugs Market 2016-2020
出版日期: 2016年03月03日 內容資訊: 英文 53 Pages
簡介

全球病毒性結膜炎治療藥的市場,預計從2016年到2020年以2.41%的年複合成長率 (CAGR) 擴大。

本報告提供全球病毒性結膜炎治療藥的市場調查,市場及產品概要,主要供應商的提供產品,疾病概要,開發平台趨勢,整體市場及各投藥途徑、各地區的市場規模的變化與預測,市場的影響因素分析,主要趨勢,主要供應商簡介等彙整資料。

第1章 摘要整理

第2章 調查範圍

  • 市場概要
  • 主要供應商的產品

第3章 市場調查手法

  • 調查手法
  • 經濟指標

第4章 簡介

  • 主要市場焦點

第5章 疾病概要

  • 結膜炎
  • 病毒性結膜炎
  • 徵兆、症狀
  • 診斷
  • 管理
  • 流行病學
  • 經濟負擔

第6章 開發平台分析

  • FST-100
  • APD-209眼科用藥
  • SPL7013
  • EKC-Cide
  • PP-001

第7章 市場環境

  • 市場概要
  • 市場規模、預測
  • 美國的病毒性結膜炎治療藥市場
  • 波特的五力分析

第8章 市場分析:各投藥途徑

  • 外用
  • 口服
  • 玻璃體內

第9章 市場分析:各地區

  • 全球市場的變化與預測:各地區
  • 南北美洲
  • 歐洲、中東、非洲
  • 亞太地區

第10章 市場成長因素

  • 意識的擴大
  • 未滿足需求
  • 高發病率

第11章 市場成長因素的影響

第12章 市場課題

  • 低的診斷率
  • 副作用、低的有效性
  • 對現有療法的滿足
  • 替代療法的可用性

第13章 成長因素與課題的影響

第14章 市場趨勢

  • 策略性聯盟、M&A
  • 非標籤藥物藥物的利用
  • R&D的活躍

第15章 業者情勢

  • Akorn
  • Alcon
  • Allergan
  • Bausch & Lomb
  • 其他卓越供應商

第16章 附錄

第17章 關於Technavio

目錄
Product Code: IRTNTR8392

About Viral Conjunctivitis Drugs

Viral conjunctivitis, or pink eye, is a type of infectious conjunctivitis that is commonly caused by an adenovirus. Herpes simplex virus (HSV), picornavirus (enterovirus 70, Coxsackie A24), varicella-zoster virus, poxvirus (molluscum contagiosum and vaccinia), and human immunodeficiency virus (HIV) are some of the other viruses that are responsible for the infection. Discomfort through watery discharge is the main symptom of this highly contagious condition. It is often associated with keratoconjunctivitis, which results in slightly blurred vision. No specific treatment option is available for the infection, which heals by itself in 2-3 weeks. Antibiotics and anti-inflammatory drugs are used only if the condition persists. In certain instances, when the infection is serious or persists for weeks, topical antiviral drugs are used. Corneal lesions persist for months even after the condition heals.

Technavio's analysts forecast the global viral conjunctivitis drugs market to grow at a CAGR of 2.41% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global viral conjunctivitis drugs market for 2016-2020. To calculate the market size, the report considers revenue generated from the sales of branded, generic, and off-label drugs used for the treatment and prevention of viral conjunctivitis.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Viral Conjunctivitis Drugs Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Akorn
  • Alcon
  • Allergan
  • Bausch & Lomb

Other Prominent Vendors

  • Adenovir Pharma
  • Marinomed Biotechnologie
  • Mediolanum Laboratoires
  • NanoViricides
  • Nicox
  • Novartis
  • Panoptes Pharma
  • Rapid Pathogen Screening
  • Shire
  • Starpharma
  • Valeant Pharmaceuticals

Market driver

  • Rising awareness
  • For a full, detailed list, view our report

Market challenge

  • Low diagnosis rate
  • For a full, detailed list, view our report

Market trend

  • Use of off-label drugs
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Disease overview

  • Conjunctivitis
  • Viral conjunctivitis
  • Signs and symptoms
  • Diagnosis
  • Management
  • Epidemiology
  • Economic burden

PART 06: Pipeline analysis

  • FST-100
  • APD-209 eye drops
  • SPL7013
  • EKC-Cide
  • PP-001

PART 07: Market landscape

  • Market overview
  • Market size and forecast
  • Viral conjunctivitis drugs market in US
  • Five forces analysis

PART 08: Market segmentation by route of administration

  • Topical
  • Oral
  • Intravitreal

PART 09: Geographical segmentation

  • Global viral conjunctivitis drugs market by geography 2015-2020
  • Viral conjunctivitis drugs market in Americas
  • Viral conjunctivitis drugs market in EMEA
  • Viral conjunctivitis drugs market in APAC

PART 10: Market drivers

  • Rising awareness
  • Unmet needs for viral conjunctivitis
  • High prevalence

PART 11: Impact of drivers

PART 12: Market challenges

  • Low diagnosis rate
  • Adverse effects and limited efficacy of drugs
  • Satisfaction with existing therapies
  • Availability of alternative therapies

PART 13: Impact of drivers and challenges

PART 14: Market trends

  • Strategic alliances and M&A
  • Use of off-label drugs
  • Rise in R&D

PART 15: Vendor landscape

  • Akorn
  • Alcon
  • Allergan
  • Bausch & Lomb
  • Other prominent vendors

PART 16: Appendix

  • List of abbreviations

PART 17: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Types of conjunctivitis
  • Exhibit 03: Major types of viral conjunctivitis
  • Exhibit 04: Signs and symptoms of types of viral conjunctivitis
  • Exhibit 05: Diagnostic algorithm for viral conjunctivitis
  • Exhibit 06: Drugs used to treat conjunctivitis
  • Exhibit 07: Comparison of prevalent rates in different types of conjunctivitis among adults and pediatric population (%)
  • Exhibit 08: Global viral conjunctivitis drugs market: Pipeline portfolio
  • Exhibit 09: Global viral conjunctivitis drugs market 2015-2020 ($ millions)
  • Exhibit 10: Snapshot of global viral conjunctivitis drugs market
  • Exhibit 11: Percentage share of US in the global viral conjunctivitis drugs market 2015
  • Exhibit 12: Viral conjunctivitis drugs market in US 2015-2020 ($ millions)
  • Exhibit 13: Five forces analysis
  • Exhibit 14: Global viral conjunctivitis drugs market segment by route of administration
  • Exhibit 15: Global viral conjunctivitis drugs market by geography 2015
  • Exhibit 16: Viral conjunctivitis drugs market by geography 2015-2020 ($ millions)
  • Exhibit 17: Viral conjunctivitis drugs market in Americas 2015-2020 ($ millions)
  • Exhibit 18: Viral conjunctivitis drugs market in EMEA 2015-2020 ($ millions)
  • Exhibit 19: Viral conjunctivitis drugs market in APAC 2015-2020 ($ millions)
  • Exhibit 20: Global viral conjunctivitis drugs market: YoY growth and revenue based on geography 2015-2020
  • Exhibit 21: Impact of drivers
  • Exhibit 22: Impact of drivers and challenges
  • Exhibit 23: Akorn: YOY growth and revenue generated from ophthalmic segment 2011-2013 ($ millions)
  • Exhibit 24: Akorn: Key takeaways
  • Exhibit 25: Alcon: Business segmentation by revenue 2014
  • Exhibit 26: Alcon: YoY growth and revenue generated from sales of ophthalmic products 2011-2014 ($ billions)
  • Exhibit 27: Alcon: Key takeaways
  • Exhibit 28: Allergan: Key takeaways
  • Exhibit 29: Bausch & Lomb: Key takeaways
Back to Top